TB-500
- Category
- Tissue Repair & Recovery
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A synthetic fragment of thymosin beta-4, marketed for tendon, muscle, and ligament recovery. The fragment's evidence is limited to preclinical work; human safety and efficacy have not been established. The cited dry-eye trial concerns full-length thymosin beta-4. Because thymosin beta-4 drives new blood-vessel growth, a theoretical tumor concern is unresolved. Not FDA-approved, restricted by the FDA over safety, and mostly sold as unregulated products online.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
TB-500 is a synthetic 7-amino-acid fragment (amino acids 17-23) of Thymosin Beta-4, a naturally occurring 43-amino-acid protein that your body produces in high concentrations at injury sites. It is one of the first genes activated after tissue damage and plays a central role in wound healing by promoting cell migration and the growth of new blood vessels. TB-500 is widely used in the recovery and regenerative medicine space for its potential to accelerate healing of muscles, tendons, ligaments, and other soft tissues.
How it works in the body
A synthetic fragment of the active region of thymosin beta-4. The fragment contains part of thymosin beta-4's actin-binding region, but its proposed actin regulation and downstream repair effects have not been established as equivalent to those of the full protein.
Research overview
TB-500 is proposed to work by regulating actin, a key structural protein inside cells that controls cell movement and shape, helping cells migrate to injury sites, promoting the formation of new blood vessels, and supporting stem cell differentiation. These proposed effects have not been established as equivalent to those of full-length thymosin beta-4. Clinical development cited here concerns full-length thymosin beta-4 products, not the TB-500 fragment. FDA's fragment-specific review identified no clinical studies establishing TB-500's safety or efficacy.
Who researches TB-500?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching hair restoration options
Explored for effects on hair follicle stimulation or hair regrowth.
People researching cognitive enhancement
Studied for neuroprotective effects, memory, or cognitive performance.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
Important considerations for
Those with Active cancer
HighTB-500 promotes cell migration and angiogenesis, which may accelerate tumor growth or metastasis.
Those who are pregnant or breastfeeding
AbsoluteNo human reproductive safety data.
Those with Recent head injury with active bleeding
ModerateAngiogenic properties may complicate recovery from hemorrhagic injuries.
Safety & interactions
Do not use if
Active cancer
HighTB-500 promotes cell migration and angiogenesis, which may accelerate tumor growth or metastasis.
Recent head injury with active bleeding
ModerateAngiogenic properties may complicate recovery from hemorrhagic injuries.
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
Not FDA-approved for any indication
HighFDA Drugs (no approved NDA/BLA); RegeneRx/HLB pipelines still in trials
FDA's drug reviewers found safety concerns and recommended against listing it; compounding is limited to the conditions of a draft interim HHS policy
HighFDA, Certain Bulk Drug Substances That May Present Significant Safety Risks (503A Category 2); BSCG TB-500 status article
Promotes angiogenesis; theoretical concern for tumor vascularization
TheoreticalPreclinical oncology literature (Tb4 upregulation in tumor progression); mechanism
Limited long-term human safety data
ModerateRGN-259/RGN-352 trial durations (weeks); absence of long-term studies
Full-length thymosin beta-4's ARISE-3 dry-eye trial missed its co-primary endpoints; this was not a TB-500 fragment trial
ModerateOphthalmology Times, HLB misses primary endpoint in phase 3 SEER-3 (2024); RegeneRx ARISE-3 results
Unregulated products sold online
HighFDA research-chemical warnings; BSCG/independent peptide purity analyses
Interaction summary(6)
Rated by direction with this peptide
Anti-VEGF / anti-angiogenic therapy (e.g., bevacizumab, ranibizumab)
CautionTheoreticalTb4's pro-angiogenic activity could theoretically oppose anti-VEGF drugs (in cancer or wet AMD) or promote unwanted vascularization; no human interaction data, but mechanistically opposing directions warrant caution.
Mechanism (Tb4 angiogenesis literature); FDA Category 2 safety rationale
Active malignancy / cytotoxic chemotherapy
CautionTheoreticalPreclinical data link elevated Tb4 to tumor-cell migration, EMT and metastasis, so introducing exogenous Tb4 during active cancer or chemotherapy is a theoretical concern; not demonstrated clinically.
Preclinical oncology literature (Tb4 in colorectal/melanoma progression)
Antiplatelet / anticoagulant post-PCI regimen (aspirin, clopidogrel, heparin)
NeutralLowIn the RGN-352 phase 2 acute-MI trial, IV Tb4 was given on top of standard post-angioplasty antiplatelet/anticoagulant care with no reported pharmacokinetic or bleeding interaction.
ClinicalTrials.gov NCT01311518 (RGN-352 AMI)
Corticosteroids (topical or systemic)
ProtectiveTheoreticalSteroids delay corneal/epidermal healing; Tb4's healing action may offset that deficit, and the two were combined in the ocular program. Potentially favorable but unproven; anti-inflammatory effects may also be additive.
Mechanism + RGN-259 ocular trial design
BPC-157 and other regenerative peptides
NeutralTheoreticalUsing TB-500 with BPC-157 or other regenerative peptides rests on an assumption of complementary healing pathways; there are no controlled data on the combination's efficacy or safety.
No clinical studies
CYP450-metabolized small-molecule drugs (general)
NeutralTheoreticalAs a peptide, Tb4 is degraded by peptidases and is not a CYP450 substrate/inhibitor, so classic pharmacokinetic drug-drug interactions are not expected; absence of interaction is inferred from pharmacology, not formally studied.
Peptide pharmacology (no CYP metabolism); no dedicated DDI studies
Known risks(6)
Not FDA-approved for any indication
FDA's drug reviewers found safety concerns and recommended against listing it; compounding is limited to the conditions of a draft interim HHS policy
Promotes angiogenesis — theoretical concern for tumor vascularization
Limited long-term human safety data
Full-length thymosin beta-4's ARISE-3 dry-eye trial missed its co-primary endpoints; this was not a TB-500 fragment trial
Unregulated products sold online
Drug interactions(2)
BPC-157
BPC-157 promotes angiogenesis and TB-500 is proposed to modulate actin and cell migration. There are no controlled data on the combination's efficacy or safety.
GHK-Cu
TB-500 is proposed to aid cell migration and GHK-Cu extracellular matrix remodeling. There are no controlled data on the combination's efficacy or safety.
Research & benefits
Evidence base
- Evidence Level
- Preclinical
- Total Studies
- 50
- Human Studies
- 0
TB-500 fragment has no established human safety or efficacy evidence. The cited Phase I–III programs concern full-length thymosin beta-4, including RGN-259 eye drops, and cannot establish benefits or safety for injected TB-500.
Researched for(7)
Rated by confidence in the evidence
Wound healing
MediumThe 42–61% result came from rat wounds treated with full-length thymosin beta-4. Its human ulcer trials do not establish TB-500 fragment efficacy.
PMC8560715 (Frontiers review, Tb4 function/application); RGN-137 phase 2 program (RegeneRx); Sosne et al. wound-healing studies
Cardiac repair
LowFull-length thymosin beta-4 has preclinical cardiac findings. The cited RGN-352 record does not establish human scar reduction, and no TB-500 fragment cardiac trial was identified.
Bock-Marquette et al. Nature 2004;432:466-72; Smart et al. Nature 2007; ClinicalTrials.gov NCT01311518 (RGN-352, incomplete); NCT05984134 (ongoing)
Corneal healing
MediumA small full-length thymosin beta-4 eye-drop trial showed a nonsignificant four-week healing trend; it did not test TB-500.
Ophthalmology Times (SEER-3 miss, 2024); RegeneRx ARISE-3 pooled results; ClinicalTrials.gov NCT02974907 (ARISE-2)
Neuroprotection
LowAnimal brain-injury studies show tissue remodeling and better functional recovery, no human trials yet.
Morris DC et al. PMID 23045978 (Treatment of neurological injury with thymosin beta4); Zhang et al. J Int Med Res 2020 (10.1177/2058739220934559)
Anti-inflammatory
LowMechanism and animal data show reduced immune-cell infiltration and swelling, with limited human evidence.
PMC8560715 (Frontiers review); Santra/Zhang miR-146a-TLR mechanism; Sosne et al. ocular anti-inflammatory studies
Anti-fibrotic
LowAnimal studies show less liver and lung scarring, with fewer scar-forming cells.
PMID 28965947 (Tb4 attenuates liver fibrosis via suppressing Notch); PMC9187458 (Tb4 protects against cardiac fibrosis post-MI, mice)
Hair growth
LowMouse studies show activated follicle stem cells and faster hair growth, no human data.
Philp D et al. FASEB J 2004 (10.1096/fj.03-0244fje); PMC4470810 (Thymosin Beta-4 Induces Mouse Hair Growth, PLoS One)
Benefits(7)
Wound healing
Cardiac repair
Corneal healing
Neuroprotection
Anti-inflammatory
Anti-fibrotic
Hair growth
Key studies(5)
Malinda KM et al.
J Invest Dermatol
1999
Full-length thymosin beta-4 in rats: +42% re-epithelialization at day 4 and +61% at day 7, with increased collagen and angiogenesis. Not a TB-500 fragment study.
Srivastava D, Saxena A, Dimaio JM, Bock-Marquette I
Ann NY Acad Sci
2007
Full-length thymosin beta-4 increased ILK/Akt activity and improved myocyte survival and cardiac function in mice; not a TB-500 fragment study.
Ruff D et al.
Ann NY Acad Sci
2010
Full-length thymosin beta-4 was well tolerated during short-term intravenous testing, without dose-limiting toxicity or serious adverse events. This does not establish TB-500 fragment safety.
Treadwell T et al.
Ann NY Acad Sci
2012
Full-length thymosin beta-4: two Phase II stasis- and pressure-ulcer trials reported healing almost a month sooner among patients whose wounds healed. Not a TB-500 trial.
Sosne G et al.
Int J Mol Sci
2023
Full-length thymosin beta-4 eye drops: 6/10 versus 1/8 healed at four weeks; p=0.0656. This was not a TB-500 fragment trial.
What research suggests over time
Weeks 2-4
Practitioner-reportedReduced injury-site inflammation reported anecdotally by users; not established in human trials.
Months 2-3
Preclinical onlyCell migration and tissue repair signals in preclinical models; thymosin beta-4 mechanism on actin polymerization.
Long-term
Preclinical onlyNo validated human long-term timeline. FDA safety concerns remain after nomination withdrawal; TB-500 is not on the final 503A bulks list; in a draft interim policy posted October 28, 2026 and open for public comment until mid-November, HHS said it does not intend to act against limited compounding under conditions.
Regulation & availability
Why researchers look at it
TB-500 fragment has no established human efficacy or safety evidence. The cited ophthalmic and intravenous programs concern full-length thymosin beta-4. Its former Category 2 nomination was withdrawn in April 2026. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against limited compounding of TB-500 acetate injections under conditions; that is not an approval.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- TB-500 is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound TB-500 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing TB-500; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records. The seven-amino-acid fragment was not reclassified as a protein biologic under the greater-than-40-amino-acid definition. RGN-259 is a separate full-length thymosin beta-4 ophthalmic product; its trials do not establish TB-500 fragment efficacy.
- WADA status
- Banned — S2.3 category (Growth Factors and Growth Factor Modulators). Well-known in horse racing doping.
- Prescribability
- TB-500 is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound TB-500 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing TB-500; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
- Availability
- Not FDA-approved. The former Category 2 nomination was withdrawn in April 2026, without establishing Category 1 status. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound TB-500 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. A clinic's offering does not show that it meets those conditions. RGN-259 development concerns full-length thymosin beta-4 eye drops, not the TB-500 fragment.
International status
EU
Not approved
UK
Not approved
US
TB-500 is not FDA-approved and is not on FDA's list of bulk substances pharmacies may use for compounding. On October 28, 2026, HHS posted a draft interim policy, open for public comment until mid-November, saying it does not intend to act against licensed pharmacies and physicians that compound TB-500 acetate for an individual patient's prescription under conditions that include: a single-ingredient injection under the skin or into muscle made from a tested ingredient from an FDA-registered facility. That is enforcement discretion, not approval, and HHS can withdraw it. FDA's drug reviewers had recommended against listing TB-500; FDA's Pharmacy Compounding Advisory Committee voted in favor in July 2026, as HHS's October 2026 policy records.
Canada
Not authorized as an approved TB-500 product; Health Canada warns about unauthorized injectable TB-500. A lawful compounding pathway was not verified.
Australia
Not TGA-approved. Any compounding or supply requires an applicable legal exemption and compliance with professional and jurisdictional requirements; a prescription alone does not establish lawful access.
Regulatory timeline(5)
- 2010Phase I safety study of full-length thymosin beta-4, not the TB-500 fragmentSafe at IV doses up to 1260mg/day x14 days
- 2012Phase II wound healingFull-length thymosin beta-4 trials reported healing almost a month sooner among stasis- and pressure-ulcer patients whose wounds healed; this was not a TB-500 fragment trial.
- 2023FDA Category 2Restricted from compounding
- 2023Phase III cornealFull-length thymosin beta-4 eye drops: 6/10 healed versus 1/8 on placebo at four weeks; p=0.0656. This was not TB-500.
- 2026-10-28HHS draft interim compounding policyHHS posts a draft interim, non-binding enforcement-discretion policy covering 503A compounding of TB-500 acetate under conditions (Federal Register Doc. 2026-22192, scheduled for Federal Register publication October 30, 2026; open for public comment until mid-November). Not an approval; not added to the 503A bulks list.
Sources & FAQs
Research sources(5)
Frequently asked questions(5)
TB-500 vs Thymosin Beta-4?
TB-500 is a synthetic fragment corresponding to the active region of thymosin beta-4 (aa 17-23, Ac-LKKTETQ). N-terminal acetylation enhances stability. Equivalent activity and safety have not been established; the fragment and full-length protein are different molecules.
Side effects?
TB-500 has no established human trial safety profile. Safety findings from trials of full-length thymosin beta-4 do not establish the safety of TB-500.
Cardiac benefits?
Preclinical cardiac findings concern full-length thymosin beta-4. The cited RGN-352 program does not establish a completed Phase II scar-reduction result. TB-500 has no established human cardiac benefit or approved cardiac indication.
Hair growth?
Preclinical evidence strong: follicle stem cell activation, faster growth in transgenic mice. No human hair trials.
How does it work?
TB-500 contains an actin-binding-region sequence from thymosin beta-4. Whether it reproduces the full protein's actin regulation and other repair mechanisms remains unresolved.